Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2025
Business Overview: InMed is a pharmaceutical drug development company with two reportable segments: Pharma (R&D of small molecule drug candidates for Alzheimer's, dry AMD, and Epidermolysis Bullosa) and Commercial (BayMedica, LLC, which manufactures and sells bulk rare cannabinoids for the health and wellness sector). The Company is a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric (USD) | 3 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2024 |
|---|---|---|---|
| Total Revenue | $820,188 | $1,940,309 | $2,376,345 |
| Gross Profit | $184,194 | $587,353 | $954,307 |
| Gross Margin | 22.5% | 30.3% | 40.2% |
| Net Loss | $(2,028,223) | $(3,755,122) | $(4,252,892) |
| Net Loss Per Share (Basic/Diluted) | $(0.51) | $(0.95) | $(6.43) |
| Cash & Cash Equivalents | $6,954,834 | $6,954,834 | $3,419,422 |
| Total Current Assets | $8,788,654 | $8,788,654 | $N/A |
| Total Current Liabilities | $1,479,993 | $1,479,993 | $N/A |
| Accumulated Deficit | $(120,993,014) | $(120,993,014) | $(113,328,651) |
Liquidity: As of December 31, 2025, the Company held approximately $7.0 million in cash, cash equivalents, and short-term investments. Management estimates this is sufficient to fund operations into the fourth quarter of calendar 2026, contingent on BayMedica revenue realization.
Material Changes vs. Prior Period
- Revenue Decline: Commercial segment revenue decreased 26% ($292k) for the three months and 18% ($436k) for the six months ended December 31, 2025, compared to the prior year. Management attributes this to market uncertainty regarding synthetic cannabinoids and strategic price reductions to attract customers.
- Margin Compression: Gross margin for the Commercial segment dropped significantly due to lower sales volumes and a $70,000 inventory write-down to net realizable value during the period.
- Expense Reduction: Total operating expenses decreased by approximately 16% for the three months and 9% for the six months compared to the prior year, driven by reduced external contractor costs and lower professional fees in the Pharma segment.
- Finance Expense Elimination: Finance expenses were $0 for the current period, a decrease of $351,549 from the prior year, as one-time non-recurring fees related to the Standby Equity Purchase Agreement (SEPA) incurred in December 2024 did not recur.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The Company has concluded there is substantial doubt about its ability to continue as a going concern within one year of the issuance date. This is due to recurring losses, negative cash flows, and an accumulated deficit of $121.0 million. Future viability depends on raising additional capital.
Regulatory Risk (H.R. 5371): The signing of the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" poses a material threat to BayMedica. If enacted in its current form on November 12, 2026, it would prohibit certain aspects of BayMedica's business and inventory of rare, non-intoxicating cannabinoids. The Company is evaluating options, including divestiture or pivoting manufacturing, but has not made definitive decisions.
Legal Contingency (Patent License Matter): BayMedica is involved in arbitration with a third-party Licensor regarding a technology license agreement. The Licensor claims BayMedica owes approximately $3.4 million in annual payments for 2022-2024 and seeks a declaration of liability for future minimum payments of approximately $2.3 million annually. BayMedica disputes these claims, asserting they are statute-barred. An unfavorable outcome could have a material adverse impact on the Company.
Outlook: The Pharma segment continues R&D on INM-901 (Alzheimer's), INM-089 (dry AMD), and INM-755 (Epidermolysis Bullosa). INM-901 completed pharmacokinetic studies in large animal models. The Company expects R&D expenses to increase significantly in future periods as clinical development progresses.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $7.0 million cash balance to fund operations through Q4 2026, given the substantial doubt disclosure.
- Legislative Impact: Monitor the status of H.R. 5371 and potential amendments that could affect BayMedica's ability to sell its inventory of rare cannabinoids.
- Arbitration Outcome: Track the "Patent License Matter" arbitration, specifically the summary dismissal motion scheduled for May 6, 2026, and the potential liability of up to $5.7 million in past and future payments.
- Capital Raising: Assess the Company's ability to secure additional equity or debt financing, noting the recent sale of 115,000 shares under the SEPA for $120,898 in January 2026.
- Inventory Valuation: Review the $70,000 inventory write-down and the total inventory reserve of $278,737 to understand the risk of further write-offs if the regulatory environment tightens.